Association of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) with uric acid among adults with elevated community exposure to PFOA

Environmental Health Perspectives

Volumn 118, Issue 2, 2010, Pages 229-233

  Steenland, Kyle ^a   Tinker, Sarah ^a   Shankar, Anoop ^b   Ducatman, Alan ^b  

^a EMORY UNIVERSITY   (United States)

^b WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

PFOA; PFOS; Uric acid

Indexed keywords

FLUOROCARBON; PERFLUOROOCTANESULFONIC ACID; PERFLUOROOCTANOIC ACID; URIC ACID;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CHEMICAL INDUSTRY; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; FEMALE; HUMAN; HYPERURICEMIA; MALE; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED STATES; WATER CONTAMINATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALKANESULFONIC ACIDS; ENVIRONMENTAL POLLUTANTS; FEMALE; FLUOROCARBONS; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; OCTANOIC ACIDS; OHIO; URIC ACID; WEST VIRGINIA; YOUNG ADULT;

EID: 77249103036     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.0900940     Document Type: Article

References (36)

1. Calafat AM, Wong LY, Kuklenyik Z, Reidy JA, Needham LL. 2007. Polyfluoroalkyl chemicals in the U.S. population: data from the National Health and Nutrition Examination Survey (NHANES) 2003-2004 and comparisons with NHANES 1999-2000. Environ Health Perspect 115:1596-1602.
2. Chen H, Mosley TH, Alonso A, Huang X. 2009. Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 169(9):1064-1069.
3. Costa G, Sartori S, Consonni D. 2009. Thirty years of medical surveillance in perfluooctanoic acid production workers. J Occup Environ Med 51(3):364-372.
4. Dimitroula HV, Hatzitolios AI, Karvounis HI. 2008. The role of uric acid in stroke: the issue remains unresolved. Neurologist 14(4):238-242.
5. Emmett EA, Zhang H, Shofer FS, Zhang H, Freeman D, Desai C, etal. 2006. Community exposure to perfluorooctanoate: relationships between serum levels and certain health parameters. J Occup Environ Med 48(8):771-779.
6. Eraly SA, Vallon V, Rieg T, Gangoiti JA, Wikoff WR, Siuzdak G, etal. 2008. Multiple organic anion transporters contribute to net renal excretion of uric acid. Physiol Genomics 33(2):180-192.
7. Fang J, Alderman MH. 2000. Serum uric acid and cardiovascular mortality the NHANES I. Epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA. 283(18):2404-2410.
8. Feig DI, Kang DH, Nakagawa T, Mazzali M, Johnson RJ. 2006. Uric acid and hypertension. Curr Hypertens Rep 8(2):111-115.
9. Feig DI, Soletsky B, Johnson RJ. 2008. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 300(8):924-932.
10. Flaherty JM, Connolly PD, Decker ER, Kennedy SM, Ellefson ME, Reagan WK, etal. 2005. Quantitative determination of perfluorooctanoic acid in serum, and plasma by liquid chromatography mass spectrometry. J Chromatogr B 819(2):329-338.
11. Frisbee SJ, Brooks AP, Maher A, Flensborg P, Arnold S, Fletcher T, etal. 2009. The C8 Health Project: design, methods, and participants. Environ Health Perspect 117:1873-1882.
12. Hakoda M, Masunari N, Yamada M, Fujiwara S, Suzuki G, Kodama K, etal. 2005. Serum uric acid concentration as a risk factor for cardiovascular mortality: a longterm cohort study of atomic bomb survivors. J Rheumatol 32:906-912.
13. Hayden MR, Tyagi SC. 2004. Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: the urate redox shuttle. Nutr Metab 1(10):1-15; doi:10.1186/1743-7075-1-10 [Online 19 October 2004].
14. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, et al. 2003. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41(6):1183-1190; doi:10.1161/01.HYP.0000069700.62727.C5. [Online 21 April 2003].
15. Lau C, Anitole K, Hodes C, Lai D, Pfahles-Hutchens A, Seed J. 2007. Perfluoroalkyl acids: a review of monitoring and toxicological findings. Toxicol Sci 99(2):366-394.
16. Leonard RC, Kreckmann KH, Sakr CJ, Symons JM. 2008. Retrospective cohort mortality study of workers in a polymer production plant including a reference population of regional workers. Ann Epidemiol 18(1):15-22.
17. Longnecker MP, Smith CS, Kissling GE, Hoppin JA, Butenhoff JL, Decker E, etal. 2008. An interlaboratory study of perfluorinated alkyl compounds levels in human plasma. Environ Res 107:152-159; doi:10.1016/j.envres.2008.01.005 [Online 4 March 2008].
18. MacNeil J, Steenland K, Shankar A, Ducatman A. 2009. A cross-sectional analysis of type II diabetes in a community with exposure to perfluorooctanoic acid (PFOA). Environ Res 109(8):992-1003; doi:10.1016/j.envres.2009.08.002 [Online 8 September 2009].
19. Mellen PB, Bleyer AJ, Erlinger TP, Evans GW, Nieto FJ, Wagenknecht LE, etal. 2006. Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study. Hypertension 48(6):1037-1042.
20. Nakagawa H, Hirata T, Terada T, Jotubha P, Miura D, Harada KH, etal. 2008. Roles of organic anion transporters in the renal excretion of perfluorooctanoic acid. Basic Clin Pharmacol Toxicol 103:(1)1-8.
21. Olsen GW, Burris JM, Burlew MM, Mandel JH. 2000. Plasma cholecystokinin and hepatic enzymes, cholesterol and lipoproteins in ammonium perfluorooctanoate production workers. Drug Chem Toxicol 23(4):603- 620.
22. Olsen GW, Burris JM, Burlew MM, Mandel JH. 2003. Epidemiologic assessment of worker serum perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) concentrations and medical surveillance examinations. J Occup Environ Med 45(3):260-270.
23. Olsen GW, Burris JM, Mandel JH, Zobel LR. 1999. Serum perfluorooctane sulfonate and hepatic and lipid clinical chemistry tests in fluorochemical production employees. J Occup Environ Med 41(9):799-806.
24. Olsen GW, Burris J, Ehresman D, Forehlich J, Seaca A, Butenhoff J, etal. 2007. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ Health Perspect 115:1298-1305.
25. Olsen GW, Zobel LR. 2007. Assessment of lipid, hepatic, and thyroid parameters with serum perfluorooctanoate (PFOA) concentrations in fluorochemical production workers. Int Arch Occup Environ Health 81(2):231-246.
26. Panaretakis T, Shabalina IG, Grander D, Shosan MC, DePierre JW. 2001. Reactive oxygen species and mitochondria mediate the induction of apoptosis in human hepatoma HepG2 cells by the rodent peroxisome proliferator and hepatocarcinogen, perfluorooctanoic acid. Toxicol Appl Pharmacol 173 (1):56-64.
27. Patterson RA, Horsley ET, Leake DS. 2003. Prooxidant and anti-oxidant properties of human serum ultrafiltrates toward LDL: important role of uric acid. J Lipid Res 44(3):512-521.
28. Sakr CJ, Kreckmann KH, Green JW, Gillies PJ, Reynolds JL, Leonard RC. 2007a. Cross-sectional study of lipids and liver enzymes related to a serum biomarker of exposure (ammonium perfluorooctanoate or APFO) as part of a general health survey in a cohort of occupationally exposed workers. J Occup Environ Med 49(10):1086-1096.
29. Sakr CJ, Leonard RC, Kreckmann KH, Slade MD, Cullen MR. 2007b. Longitudinal study of serum lipids and liver enzymes in workers with occupational exposure to ammonium perfluorooctanoate. J Occup Environ Med 49(8):872-879.
30. Shankar A, Klein R, Klein BE, Nieto FJ. 2006. The association between serum uric acid level and long-term incidence of hypertension: population-based cohort study. J Hum Hypertens 20(12):937-945.
31. Steenland K, Jin C, MacNeil J, Lally C, Ducatman A, Vieira V, etal. 2009a. Predictors of PFOA levels in a community surrounding a chemical plant. Environ Health Perspect 117:1083-1088.
32. Steenland K, Tinker S, Frisbee S, Ducatman A, Vaccarino A. 2009b. Association of perfluorooctanic acid and perfluorooctane sulfonate with serum lipids among adults living near a chemical plant. Am J Epidemiol 170(10):1268-1278; doi: 10.1093/aje/kwp279 [Online 21 October 2009].
33. Sundström J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS. 2005. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 45(1):18-20.
34. U.S. EPA. 2005. Draft Risk Assessment of the Potential Human Health Effects Associated with Exposure to Perflouroctanoic Acids and Its Salts. Available: http://www.epa.gov/oppt/pfoa/pubs/pfoarisk.pdf [accessed 11 December 2009].
35. Wannamethee SG. 2005. Serum uric acid and risk of coronary heart disease. Curr Pharm Des 11(32):4125-4132.
36. Yao X, Zhong L. 2005. Genotoxic risk and oxidative DNA damage in HepG2 cells exposed to perfluorooctanoic acid. Mutat Res 587(1-2):38-44; doi: 10.1016/j.mrgentox.2005.07.010 [Online 10 October 2005].